The phase 1 study was funded by Ceregene, which was acquired in October 2013 by Sangamo BioSciences.
Dr. Bartus disclosed that he is a consultant for Sangamo BioSciences.
News
Nerve growth factor gene therapy delivered safely in Alzheimer’s patients
